Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism

被引:20
作者
Baleeiro, R. B. [1 ]
Barbuto, J. A. M. [1 ]
机构
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Tumor Immunol, BR-05508000 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
tumor escape mechanisms; CD83; dendritic cells; immunosuppression;
D O I
10.1016/j.molimm.2008.04.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
CD83, a characteristic marker of activated dendritic cells, is also expressed by tumor cell lines from various origins and by primary lung cancers. Here, we show that CD83+ tumor cells (from a primary lung cancer and from an established breast cancer cell line) release in their culture supernatants a soluble factor that is able to block, in a dose-dependent manner, CD4+ and CD8+ T cell proliferative responses to allogeneic dendritic cells. This factor was removed from the medium by incubation in anti-CD83 covered plates, indicating that it could be one of the known soluble forms of the CD83 molecule, released in the medium by the cultured tumor cells. This phenomenon, happening in vivo, in the tumor microenvironment, could affect profoundly anti-tumor immune responses and should, therefore, be considered in immunotherapeutic approaches to cancer. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3502 / 3504
页数:3
相关论文
共 7 条
[1]
Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? [J].
Baleeiro, R. B. ;
Bergami-Santos, P. C. ;
Tomiyoshi, M. Y. ;
Gross, J. L. ;
Haddad, F. ;
Pinto, C. A. L. ;
Soares, F. A. ;
Younes, R. N. ;
Barbuto, J. A. M. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (02) :265-270
[2]
CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells [J].
Cao, WP ;
Lee, SH ;
Lu, JH .
BIOCHEMICAL JOURNAL, 2005, 385 :85-93
[3]
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity [J].
Hirano, N ;
Butler, MO ;
Xia, Z ;
Ansén, S ;
von Bergwelt-Baildon, MS ;
Neuberg, D ;
Freeman, GJ ;
Nadler, LM .
BLOOD, 2006, 107 (04) :1528-1536
[4]
The soluble form of CD83 is present at elevated levels in a number of hematological malignancies [J].
Hock, BD ;
Haring, LF ;
Steinkasserer, A ;
Taylor, KG ;
Patton, WN ;
McKenzie, JL .
LEUKEMIA RESEARCH, 2004, 28 (03) :237-241
[5]
The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells [J].
Lechmann, M ;
Krooshoop, DJEB ;
Dudziak, D ;
Kremmer, E ;
Kuhnt, C ;
Figdor, CG ;
Schuler, G ;
Steinkasserer, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1813-1821
[6]
ZHOU LJ, 1992, J IMMUNOL, V149, P735
[7]
Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83 [J].
Zinser, E ;
Lechmann, M ;
Golka, A ;
Lutz, MB ;
Steinkasserer, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (03) :345-351